David Soleimani-Meigooni, MD

Title(s)Assistant Professor, Neurology
SchoolSchool of Medicine
Address1651 4th Street, #361C
San Francisco CA 94158
Phone415-353-2057
ORCID ORCID Icon0000-0003-4197-3039 Additional info
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences


    Collapse Overview 
    Collapse Overview
    Dr. David N. Soleimani-Meigooni is a neurologist who cares for patients experiencing cognitive symptoms as a result of neurodegenerative diseases such as Alzheimer's disease. He also directs the UCSF Memory and Aging Center's lumbar puncture service (this procedure obtains a sample of cerebrospinal fluid, which is analyzed to help diagnose certain neurological diseases).

    In research, Soleimani-Meigooni focuses on advancing precision-medicine approaches to diagnosing Alzheimer's disease. He looks at using positron emission tomography (PET) to image amyloid-beta and tau (protein fragments that accumulate in the brains of people with the condition).

    Soleimani-Meigooni earned his medical degree at UCSF. He completed a residency in neurology at Washington University School of Medicine in St. Louis, followed by a fellowship in cognitive and behavioral neurology at UCSF.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. [18F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration. J Nucl Med. 2023 12 01; 64(12):1980-1989. Blazhenets G, Soleimani-Meigooni DN, Thomas W, Mundada N, Brendel M, Vento S, VandeVrede L, Heuer HW, Ljubenkov P, Rojas JC, Chen MK, Amuiri AN, Miller Z, Gorno-Tempini ML, Miller BL, Rosen HJ, Litvan I, Grossman M, Boeve B, Pantelyat A, Tartaglia MC, Irwin DJ, Dickerson BC, Baker SL, Boxer AL, Rabinovici GD, La Joie R. PMID: 37918868; PMCID: PMC10690126.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    2. Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer's disease. Brain Commun. 2023; 5(6):fcad280. Llibre-Guerra JJ, Iaccarino L, Coble D, Edwards L, Li Y, McDade E, Strom A, Gordon B, Mundada N, Schindler SE, Tsoy E, Ma Y, Lu R, Fagan AM, Benzinger TLS, Soleimani-Meigooni D, Aschenbrenner AJ, Miller Z, Wang G, Kramer JH, Hassenstab J, Rosen HJ, Morris JC, Miller BL, Xiong C, Perrin RJ, Allegri R, Chrem P, Surace E, Berman SB, Chhatwal J, Masters CL, Farlow MR, Jucker M, Levin J, Fox NC, Day G, Gorno-Tempini ML, Boxer AL, La Joie R, Rabinovici GD, Bateman R. PMID: 37942088; PMCID: PMC10629466.
      View in: PubMed   Mentions:
    3. The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort. Alzheimers Dement. 2023 11; 19 Suppl 9:S74-S88. Touroutoglou A, Katsumi Y, Brickhouse M, Zaitsev A, Eckbo R, Aisen P, Beckett L, Dage JL, Eloyan A, Foroud T, Ghetti B, Griffin P, Hammers D, Jack CR, Kramer JH, Iaccarino L, Joie R, Mundada NS, Koeppe R, Kukull WA, Murray ME, Nudelman K, Polsinelli AJ, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Carrillo MC, Rabinovici GD, Apostolova LG, Dickerson BC, LEADS Consortium. PMID: 37850549; PMCID: PMC10829523.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment. Alzheimers Res Ther. 2023 09 22; 15(1):157. Mundada NS, Rojas JC, Vandevrede L, Thijssen EH, Iaccarino L, Okoye OC, Shankar R, Soleimani-Meigooni DN, Lago AL, Miller BL, Teunissen CE, Heuer H, Rosen HJ, Dage JL, Jagust WJ, Rabinovici GD, Boxer AL, La Joie R. PMID: 37740209; PMCID: PMC10517500.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Alzheimers Dement. 2023 11; 19 Suppl 9:S98-S114. Cho H, Mundada NS, Apostolova LG, Carrillo MC, Shankar R, Amuiri AN, Zeltzer E, Windon CC, Soleimani-Meigooni DN, Tanner JA, Heath CL, Lesman-Segev OH, Aisen P, Eloyan A, Lee HS, Hammers DB, Kirby K, Dage JL, Fagan A, Foroud T, Grinberg LT, Jack CR, Kramer J, Kukull WA, Murray ME, Nudelman K, Toga A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez M, Musiek E, Onyike CU, Riddle M, Rogalski EJ, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Koeppe R, Iaccarino L, Dickerson BC, La Joie R, Rabinovici GD, LEADS Consortium. PMID: 37690109; PMCID: PMC10807231.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    6. Influence of amyloid and diagnostic syndrome on non-traditional memory scores in early-onset Alzheimer's disease. Alzheimers Dement. 2023 11; 19 Suppl 9:S29-S41. Bushnell J, Hammers DB, Aisen P, Dage JL, Eloyan A, Foroud T, Grinberg LT, Iaccarino L, Jack CR, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Nudelman K, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Touroutoglou A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez M, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG, Clark DG, LEADS Consortium. PMID: 37653686; PMCID: PMC10855009.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease. Alzheimers Dement. 2023 11; 19 Suppl 9:S49-S63. Nemes S, Logan PE, Manchella MK, Mundada NS, La Joie R, Polsinelli AJ, Hammers DB, Koeppe RA, Foroud TM, Nudelman KN, Eloyan A, Iaccarino L, Dorsant-Ardón V, Taurone A, Thangarajah M, Dage JL, Aisen P, Grinberg LT, Jack CR, Kramer J, Kukull WA, Murray ME, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Touroutoglou A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Womack KB, Wolk DA, Rabinovici GD, Carrillo MC, Dickerson BC, Apostolova LG, LEADS Consortium. PMID: 37496307; PMCID: PMC10811272.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study. Alzheimers Dement. 2023 11; 19 Suppl 9:S115-S125. Dage JL, Eloyan A, Thangarajah M, Hammers DB, Fagan AM, Gray JD, Schindler SE, Snoddy C, Nudelman KNH, Faber KM, Foroud T, Aisen P, Griffin P, Grinberg LT, Iaccarino L, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Rumbaugh M, Soleimani-Meigooni DN, Toga AW, Touroutoglou A, Vemuri P, Atri A, Beckett LA, Day GS, Graff-Radford NR, Duara R, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Womack KB, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG, LEADS Consortium. PMID: 37491668; PMCID: PMC10877673.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Alzheimers Dement. 2023 11; 19 Suppl 9:S89-S97. Eloyan A, Thangarajah M, An N, Borowski BJ, Reddy AL, Aisen P, Dage JL, Foroud T, Ghetti B, Griffin P, Hammers D, Iaccarino L, Jack CR, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Nudelman K, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Touroutoglou A, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Musiek E, Onyike CU, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Beckett L, Gao S, Carrillo MC, Rabinovici G, Apostolova LG, Dickerson B, Vemuri P, LEADS Consortium. PMID: 37491599; PMCID: PMC10808262.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort. Alzheimers Dement. 2023 11; 19 Suppl 9:S42-S48. Polsinelli AJ, Wonderlin RJ, Hammers DB, Garcia AP, Eloyan A, Taurone A, Thangarajah M, Beckett L, Gao S, Wang S, Kirby K, Logan PE, Aisen P, Dage JL, Foroud T, Griffin P, Iaccarino L, Kramer JH, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Nudelman K, Soleimani-Meigooni DN, Rumbaugh M, Toga AW, Touroutoglou A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG, LEADS Consortium. PMID: 37296082; PMCID: PMC10709525.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection. Alzheimers Dement. 2023 11; 19 Suppl 9:S8-S18. Hammers DB, Eloyan A, Taurone A, Thangarajah M, Beckett L, Gao S, Kirby K, Aisen P, Dage JL, Foroud T, Griffin P, Grinberg LT, Jack CR, Kramer J, Koeppe R, Kukull WA, Mundada NS, La Joie R, Soleimani-Meigooni DN, Iaccarino L, Murray ME, Nudelman K, Polsinelli AJ, Rumbaugh M, Toga A, Touroutoglou A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG, LEADS Consortium. PMID: 37256497; PMCID: PMC10806768.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. Brain. 2022 12 19; 145(12):4489-4505. Tanner JA, Iaccarino L, Edwards L, Asken BM, Gorno-Tempini ML, Kramer JH, Pham J, Perry DC, Possin K, Malpetti M, Mellinger T, Miller BL, Miller Z, Mundada NS, Rosen HJ, Soleimani-Meigooni DN, Strom A, La Joie R, Rabinovici GD. PMID: 35762829; PMCID: PMC10200306.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    13. Tau PET Visual Reads: Research and Clinical Applications and Future Directions. J Nucl Med. 2023 05; 64(5):822-824. Soleimani-Meigooni DN, Rabinovici GD. PMID: 37116910; PMCID: PMC10152121.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. J Nucl Med. 2022 06; 63(Suppl 1):13S-19S. Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. PMID: 35649652; PMCID: PMC9165727.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    15. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Neurology. 2022 08 09; 99(6):e594-e604. Asken BM, Tanner JA, VandeVrede L, Mantyh WG, Casaletto KB, Staffaroni AM, La Joie R, Iaccarino L, Soleimani-Meigooni D, Rojas JC, Gardner RC, Miller BL, Grinberg LT, Boxer AL, Kramer JH, Rabinovici GD. PMID: 35577574; PMCID: PMC9442622.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    16. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. Brain. 2022 04 18; 145(2):713-728. Strom A, Iaccarino L, Edwards L, Lesman-Segev OH, Soleimani-Meigooni DN, Pham J, Baker SL, Landau SM, Jagust WJ, Miller BL, Rosen HJ, Gorno-Tempini ML, Rabinovici GD, La Joie R, Alzheimer’s Disease Neuroimaging Initiative. PMID: 34373896; PMCID: PMC9014741.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    17. Pharmacokinetics of 38 Percent Silver Diamine Fluoride in Children. Pediatr Dent. 2022 Mar 15; 44(2):114-121. Ellenikiotis H, Chen KF, Soleimani-Meigooni DN, Rothen ML, Thompson B, Lin YS, Milgrom P. PMID: 35484770; PMCID: PMC9060293.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. JAMA Neurol. 2021 08 01; 78(8):961-971. Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, Palmqvist S, Olsson T, Jögi J, Stormrud E, Cho H, Ryu YH, Choi JY, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Baker S, Borroni E, Klein G, Pontecorvo MJ, Devous MD, Jagust WJ, Lyoo CH, Rabinovici GD, Hansson O. PMID: 34180956; PMCID: PMC8240013.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    19. Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females. Neurobiol Aging. 2021 09; 105:86-98. Edwards L, La Joie R, Iaccarino L, Strom A, Baker SL, Casaletto KB, Cobigo Y, Grant H, Kim M, Kramer JH, Mellinger TJ, Pham J, Possin KL, Rosen HJ, Soleimani-Meigooni DN, Wolf A, Miller BL, Rabinovici GD. PMID: 34049062; PMCID: PMC8820163.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    20. Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. Eur J Nucl Med Mol Imaging. 2021 07; 48(7):2259-2271. Provost K, Iaccarino L, Soleimani-Meigooni DN, Baker S, Edwards L, Eichenlaub U, Hansson O, Jagust W, Janabi M, La Joie R, Lesman-Segev O, Mellinger TJ, Miller BL, Ossenkoppele R, Pham J, Smith R, Sonni I, Strom A, Mattsson-Carlgren N, Rabinovici GD, Alzheimer’s Disease Neuroimaging Initiative (ADNI). PMID: 33398408; PMCID: PMC8178158.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. Cereb Cortex. 2021 01 01; 31(1):1-14. Iaccarino L, La Joie R, Edwards L, Strom A, Schonhaut DR, Ossenkoppele R, Pham J, Mellinger T, Janabi M, Baker SL, Soleimani-Meigooni D, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD. PMID: 32808011; PMCID: PMC7727356.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    22. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain. 2020 12 05; 143(11):3477-3494. Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL, Edwards L, Eser R, Gorno-Tempini ML, Jagust WJ, Janabi M, Kramer JH, Lesman-Segev OH, Mellinger T, Miller BL, Pham J, Rosen HJ, Spina S, Seeley WW, Strom A, Grinberg LT, Rabinovici GD. PMID: 33141172; PMCID: PMC7719031.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    23. Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology. 2021 02 02; 96(5):e650-e661. La Joie R, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, Soleimani-Meigooni DN, Mellinger T, Janabi M, Miller ZA, Perry DC, Pham J, Strom A, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD. PMID: 33262228; PMCID: PMC7884991.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    24. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2021 07; 48(7):2245-2258. Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, Palmqvist S, Mattsson-Carlgren N, Olsson T, Jögi J, Stormrud E, Ryu YH, Choi JY, Alzheimer’s Disease Neuroimaging Initiative, PREVENT-AD research group, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Borroni E, Klein G, Pontecorvo MJ, Devous MD, Villeneuve S, Lyoo CH, Rabinovici GD, Hansson O. PMID: 33215319; PMCID: PMC8131404.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    25. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement (Amst). 2020; 12(1):e12101. VandeVrede L, Gibbs DM, Koestler M, La Joie R, Ljubenkov PA, Provost K, Soleimani-Meigooni D, Strom A, Tsoy E, Rabinovici GD, Boxer AL. PMID: 33072846; PMCID: PMC7545921.
      View in: PubMed   Mentions: 28  
    26. Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy. JAMA Neurol. 2020 04 01; 77(4):517-521. Mantyh WG, Spina S, Lee A, Iaccarino L, Soleimani-Meigooni D, Tsoy E, Mellinger TJ, Grant H, Vandevrede L, La Joie R, Lesman-Segev O, Gaus S, Possin KL, Grinberg LT, Miller BL, Seeley WW, Rabinovici GD. PMID: 31904765; PMCID: PMC6990867.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    27. The Oxford Handbook of Adult Cognitive Disorders. Rapidly Progressive Dementia: Human Prion Diseases and an Approach for Evaluating Non-Prion Etiologies. 2019; 705-742. Soleimani-Meigooni DN and Geschwind MD. View Publication.
    28. Structural signature of sporadic Creutzfeldt-Jakob disease. Eur J Neurol. 2019 08; 26(8):1037-1043. Navid J, Day GS, Strain J, Perrin RJ, Bucelli RC, Dincer A, Wisch JK, Soleimani-Meigooni D, Morris JC, Benzinger TLS, Ances BM. PMID: 30735286; PMCID: PMC6615963.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. J Neurovirol. 2017 02; 23(1):141-146. Soleimani-Meigooni DN, Schwetye KE, Angeles MR, Ryschkewitsch CF, Major EO, Dang X, Koralnik IJ, Schmidt RE, Clifford DB, Kuhlmann FM, Bucelli RC. PMID: 27421731; PMCID: PMC5588866.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    30. Cylindrical coordinate based TG-43U1 parameters for dose calculation around elongated brachytherapy sources. J Appl Clin Med Phys. 2008 04 16; 9(2):123-142. Awan SB, Dini SA, Hussain M, Soleimani-Meigooni D, Meigooni AS. PMID: 18714281; PMCID: PMC5721703.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    31. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 2004 Feb 26; 23(8):1599-607. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM. PMID: 14985701.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells